The bidding window for Sambhv Steel Tubes Ltd IPO opened yesterday on June 25, 2025, and will close on June 27, 2025. The allotment process is expected to be finalised on June 30, 2025, with the company's shares set to be listed on both the BSE and NSE tentatively on Wednesday, July 3, 2025.
The IPO will be a book-built issue of ₹540 crore, consisting of a combination of a fresh issue of 5.37 crore shares aggregating to ₹440.00 crores and an offer for sale of 1.22 crore shares aggregating to ₹100 crores. Investors can apply with a minimum lot size of 182, requiring a minimum investment of ₹14,014. The issue price band is set in the range of ₹77 to ₹82 per share.
Nuvama Wealth Management Limited and Motilal Oswal Investment Advisors Limited are the book-running lead managers of the Sambhv Steel Tubes IPO, while Kfin Technologies Limited is the registrar for the issue.
(June 26, 2025, 5 PM)
On Day 2, Sambhv Steel Tubes IPO was subscribed 1.27 times. The public issue subscribed 1.97 times in the retail category, 0.17 times in QIB, and 3.32 times in the NII category.
Also Read : Sambhv Steel Tubes IPO Day 1 Subscription Status
The company will utilise the net proceeds from the issue towards the following objects:
According to NDTV Profit, the Grey Market Premium (GMP) of Sambhv Steel Tubes was ₹10 as of June 26, 2025, 11 a.m. This indicates that the company's shares are likely to be listed at ₹92, with an expected percentage gain/loss per share of 12.20%.
Source: NDTV Profit Media Report dated June 26, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. To read the RA disclaimer, please click here |